FDA Approved: OXBRYTA — Supplemental Application (Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.)

View source ↗

Summary

FDA approved a supplemental application for OXBRYTA (voxelotor) submitted by Global Blood Therapeutics, a Pfizer subsidiary, related to sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

SUPPL AP for OXBRYTA (VOXELOTOR)